載入中
NASDAQHealthcareBiotechnology
最新資料
US$35.2794
−US$1.6206 · -4.39%
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
一般交易時段
US$35.2794
−US$1.6206 · -4.39%
盤中時間採用ET。市場資料可能有所延遲。
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
日內區間
目前US$35.2794
52週區間
目前US$35.2794
盤中時間採用ET。市場資料可能有所延遲。
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
日內區間
目前US$35.2794
52週區間
目前US$35.2794
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 52.7萬 USD | 316.2萬 USD | — | — |
| 毛利 | — | −52.7萬 USD | −316.2萬 USD | — | — |
| 研究與開發 | 1.18億 USD | 6529.7萬 USD | 4896.2萬 USD | 3616.9萬 USD | 3478.9萬 USD |
| 銷售、一般及管理費用 | 4864.4萬 USD | 3861.9萬 USD | 4174.2萬 USD | 3016.2萬 USD | 5906.5萬 USD |
| 營業費用 | 1.66億 USD | 1.03億 USD | 9070.4萬 USD | 6633.1萬 USD | 9385.4萬 USD |
| 利息收入 | 1096萬 USD | 1155.8萬 USD | 558.4萬 USD | 149.5萬 USD | — |
| 利息支出 | 548.2萬 USD | 228.3萬 USD | 92萬 USD | 149.5萬 USD | 35.9萬 USD |
| 折舊和攤銷 | — | 52.7萬 USD | 316.2萬 USD | 318萬 USD | 261.6萬 USD |
| 營業利益 | −1.66億 USD | −1.04億 USD | −9386.6萬 USD | −6633.1萬 USD | −9385.4萬 USD |
| 淨利 | −1.84億 USD | −1.09億 USD | −9573.2萬 USD | −5679.6萬 USD | −9303.6萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$67.45
上漲空間 91.19%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年8月29日 | 1:15 | — | — |
股票分割 | 2020年3月3日 | 1:8 | — | — |
已生效 2022年8月29日
1:15
已生效 2020年3月3日
1:8
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM1.21億0.15%787.4億 USD0.19%US$278.11-0.30%
Vanguard Extended Market ETFVXF5984.78萬0.06%954億 USD0.05%US$233.82-0.50%
iShares Russell 2000 Growth ETFIWO4265.25萬0.31%139.17億 USD0.24%US$353.96-0.79%
iShares Biotechnology ETFIBB3673.49萬0.34%108.2億 USD0.44%US$204.3-1.06%
Vanguard Russell 2000 ETFVTWO2971.1萬0.16%180億 USD0.06%US$112.34-0.28%
Schwab U.S. Small-Cap ETFSCHA2440.5萬0.11%218.24億 USD0.03%US$32.705-0.26%
iShares U.S. Pharmaceuticals ETFIHE1725.82萬1.11%15.52億 USD0.37%US$99.94-0.15%
Fidelity Enhanced Small Cap ETFFESM1593.2萬0.24%64.1億 USD0.28%US$45.31-0.33%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
